A new bioengineered neuronal circuit board "BioConNet" allows scientists to artificially engineer human brain-like wiring at scale and can be used to engineer any possible circuit. The fully ...
On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when ...
DURHAM, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
BRISBANE, Calif. and EDEN PRAIRIE, Minn., April 05, 2023 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA) and Miromatrix Medical Inc. (MIRO) -- today announced an exclusive partnership aimed at advancing the ...
DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial ...
Morning Overview on MSN
Scientists grow fully working hair follicles in a lab for 1st time
Researchers affiliated with RIKEN Center for Biosystems Dynamics Research and biotech firm OrganTech have produced fully ...
An investigational product called Acellular Tissue Engineered Vessel demonstrated superior hemodialysis vascular access outcomes compared with AVFs in a phase 3 trial. A bioengineered human tissue ...
Shares of Humacyte Inc (NASDAQ: HUMA) nearly doubled on Friday after receiving full approval for its flagship SYMVESS product ...
Intermountain Medical Center participated in a trial of the first bioengineered external liver, designed to help acute liver failure patients or are not eligible for or are waiting for a transplant a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results